SLC5A2 and chronic kidney disease: The rate of new CKD diagnoses per year did not change over time, with rates of 3.0% in 2017 (when the Kidney Disease Review Committee was established), 3.3% in 2018 (when the CKD guidelines were revised), and 3.4% in 2021 (when an SGLT2 inhibitor for CKD was approved) (Fig. 2).